Yvonne Zissiadis trained as a Radiation Oncologist at the Peter MaCallum Cancer Institute, Melbourne, Australia. This was followed by a Fellowship in Breast Cancer at the Breast Cancer Institute of Australia, NSW. She then commenced work as a radiation oncologist at the Prince of Wales Hospital, Randwick, NSW. In 1999, Yvonne completed a fellowship at the Massachusetts General Hospital and then returned to her home town of Perth, Western Australia to take up the position of radiation oncologist at Royal Perth Hospital and Perth Radiation Oncology. This then became Fiona Stanley Hospital and Genesiscare WA.
Her other activities include membership of the RANZCR Education and Training committee, RANZCR Radiation Oncology Research Committee, TROG, BTG, ASTRO and ESTRO. She holds conjoint lectureship positions with the University of Western Australia and Edith Cowen University. From 2015, she has held the position of President of the Australasian Society of Breast Disease. She has contributed to the organisation of a number of conferences, teaching courses and workshops as well as registrar teaching.

Prof. Bruce Mann is Professor of Surgery at the University of Melbourne and Director of The Breast Service at the Royal Melbourne and Royal Women’s Hospital in Melbourne. He is on the council of Breast SurgANZ, the Scientific Advisory Committee of the ANZ Breast Cancer Trials Group and is past president of the Clinical Oncology Society of Australia. He has been involved in many clinical trials and much clinical and translational research regarding breast cancer, with his main research interest being tailoring treatment to the disease and the patient.

Prof. Christobel Saunders MB BS, FRCS, FRACS, FAAHMS 2017 WA Scientist of the Year is internationally recognised as one of Australia’s most prominent research-orientated cancer surgeons. She has substantially contributed to many clinical aspects of breast cancer research including clinical trials of new treatments, psychosocial, translational and health services research and is active in several areas of surgical oncology cancer research, with a particular emphasis on breast cancer. She has performed research for >25 years evaluating the efficacy and utility of therapy for early breast cancer. In the past five years, Professor Saunders has published 100 peer-reviewed journal articles (including two in The Lancet), six letters to the editor/editorials, two research reports, three book chapters and one book. She was recently awarded a $9m dollar grant to undertake research into value based healthcare in WA. She sits on boards of a number of cancer organisations including the ANZ Breast Cancer Trials Group and is President of the Breast Surgical Society of Australia and New Zealand; and is closely involved in strategic planning and management of cancer services in Western Australia as author of the WA Health Cancer Services Framework and as first A/Director, WA Cancer and Palliative Care Network , and past President of the Cancer Council WA; and nationally as past Advisory Council member of organisations such as Cancer Australia.

Dr. Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996. He continued his studies at the University of Navarra, specialising in Medical Oncology at the Clínica Universitaria de Navarra, where he continued as Assistant in the Department of Oncology from 2002. He was Associated Professor of Oncology in the Faculty of Medicine at the University of Navarra during that period. Dr. Cortés was awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. Since 2003, he has worked in the Department of Medical Oncology at the Hospital Vall d’ Hebron, Barcelona, where he is Coordinator of the Teaching and Training Programme for Residents in Oncology and Senior Specialist in the Area of Breast Cancer with a special interest in New Drugs Development. Dr. Cortés is Head of the Breast Cancer Unit and the Melanoma Unit.
In addition, he has two masters’ degree: “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.
Dr. Cortes is the author of more than 100 publications, especially about breast tumours and new drugs and more than 250 communications at different conferences. He actively participates in the development of numerous national and international clinical investigations, especially in relation to drugs directed against molecular targets and new chemotherapy agents, and he is an ad hoc reviewer of various oncology journals.
Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO), a member of the Scientific Committee of the European Society of Medical Oncology and the Scientific Committee of SOLTI group.

Dr. Richard De Boer completed his basic medical and oncology training at the Royal Melbourne Hospital and then in 1997 undertook a 3-year breast and lung cancer clinical research fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.
He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. His primary areas of clinical interest are in breast and lung cancer, with breast cancer interests focusing on endocrine therapy and mechanisms of resistance, treatment-induced bone loss and bone metastases, and biological predictors of response/survival. He is actively involved in clinical research, and is a member of the Australian New Zealand Breast Cancer Trials Group, and head of the Breast Trials group of Cancer Trials Australia. He has authored or co-authored articles appearing in journals such as the Journal of Clinical Oncology, Annals of Oncology, The Breast and British Journal of Cancer.

Prof. Alastair Thompson graduated from the University of Edinburgh, UK with Distinction in Surgery and subsequently trained as a Clinician Scientist and Fellow of the Royal College of Surgeons of Edinburgh. In 2014 he moved from the position of Professor of Surgical Oncology, Clinical Lead for the Dundee Cancer Centre/Experimental Cancer Medicine Centre and Foundation Director of the Clinical Research Centre, Dundee, UK to the Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center in Houston, Texas, specializing in breast cancer.
Achievements to date include setting up and chairing the Breast Cancer Campaign Breast Tissue Bank Board for the UK and Eire, leading the 12,000 patient UK National Audit of Screen Detected DCIS and, for 5 years to 2014, chairing the UK National Cancer Research Institute, Breast Clinical Studies Group (with oversight of 120 academic and commercial clinical studies in breast cancer). He actively contributes to a range of clinical trials in the prevention, early detection and therapy of breast cancer. He remains as UK Chief Investigator for a number of key trials including MINDACT, MA32 and SOLE and continues to chair the data monitoring committees and trials steering groups for several phase II drug trials and phase III surgical trials respectively in the UK.
Active in translational laboratory research, he built a breast cancer research program over 15 years in Dundee, including a xenograft program and tissue banking facility with a focus on the p53 network and drug development. He has successfully supervised 20 PhD or research MD students and currently has 4 students completing PhDs. The impact of over 200 peer reviewed research papers has included global firsts demonstrating the effect of drugs in vivo in animal models and in human cancers.
He continues to provide leadership in trials and clinical translational research with colleagues in Europe and Australasia while establishing clinical trials and laboratory collaborations in the US, through membership of the American Society of Clinical Oncology, American Association of Cancer Research, South West Oncology Group and Translational Breast Cancer Research Consortium.

Dr Boon H Chua is Professor of Medicine at UNSW Sydney; Consultant Radiation Oncologist, Director of Cancer and Haematology Services, and Medical Co-Director of the Program of Neurosciences, Cancer Services, Rehabilitation, Intensive Care, Radiology and Nuclear Medicine at the Prince of Wales Hospital in Sydney.
With clinical and academic subspecialisation in breast cancer, Dr Chua leads a national and international program of competitive grant-funded oncology research in collaboration with cooperative clinical trials groups worldwide. She also holds leadership positions in a diverse range of national and international organisations including Executive Board member of Breast International Group, Education Faculty member of European Society of Medical Oncology, Scientific Advisory Committee Executive of Breast Cancer Trials-ANZ, and Breast Subspecialty Group Chair of Trans Tasman Radiation Oncology Group.
Dr Chua was a senior clinical leader for redevelopment of Peter MacCallum Cancer Centre where she was Staff Specialist until November 2016. As Chair and Principal Council Representative of the RANZCR Post-Fellowship Education Committee, Dr Chua led development and implementation of the national program of continuing professional development in Radiation Oncology.

Dr. Richard De Boer completed his basic medical and oncology training at the Royal Melbourne Hospital and then in 1997 undertook a 3-year breast and lung cancer clinical research fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.
He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. His primary areas of clinical interest are in breast and lung cancer, with breast cancer interests focusing on endocrine therapy and mechanisms of resistance, treatment-induced bone loss and bone metastases, and biological predictors of response/survival. He is actively involved in clinical research, and is a member of the Australian New Zealand Breast Cancer Trials Group, and head of the Breast Trials group of Cancer Trials Australia. He has authored or co-authored articles appearing in journals such as the Journal of Clinical Oncology, Annals of Oncology, The Breast and British Journal of Cancer.

Dr Minjae Lah is a dedicated Radiation Oncologist who holds her expertise in breast and lung cancer management. She completed her undergraduate medicine and residency training in Queensland. She gained further experience in Sydney to achieve her fellowship in Radiation Oncology. Since 2004, she has been practicing in Brisbane.
In addition to her interests in innovative techniques in radiotherapy, she is a passionate supporter of multidisciplinary care in clinical decision making and delivery of cancer care. For over a decade, she has been involved in graduate medicine, Radiation Oncology and continued medical education trainings in her academic and clinical roles. She is the current Research Chair at Genesis CancerCare Queensland, leading her team in clinical research for cancer.

Jocelyn Lippey is a breast surgeon from Melbourne, Victoria. Having completed her general surgery fellowship through the Austin hosptial she underwent post fellowship training through Breast Surg ANZ at Peter MacCallum Cancer Centre in 2015 and Perth in 2016 working at Royal Perth and Fiona Stanley Hospitals.
She is a current recipient of an NBCF practitioners grant to develop a risk communication tool as part of a risk-stratified Breast screening trial as well as doing clinical work at The Northern hospital in Melbourne.
Her interests include research into breast cancer, risk communication, tailored breast screening and DCIS as well as oncoplastic and reconstructive surgery.

Nicole McCarthy
Associate Professor Nicole McCarthy MBBS (Hons), MHSc, FRACP is a Consultant Medical Oncologist at Icon Cancer Care at the Wesley Medical Centre and Wesley Hospital in Brisbane and her academic appointment is with the School of Medicine, University of Queensland . She completed a 3 year Medical oncology fellowship at the National Cancer Institute, Bethesda MD and a Masters in Health Sciences in Clinical Trial Design through Duke University. She is an academic clinician and her clinical practice and translational research focuses on the multifaceted aspects of breast cancer care and management. She led the Breast Cancer Clinical trials unit at the Royal Brisbane and Women’s Hospital for over 10 years and now provides leadership for the breast cancer clinical trials component of ICON Research Foundation Clinical Trials Unit, the largest national private oncology provider. A/Prof McCarthy is considered an opinion leader in breast cancer management at a local and national level and her own investigator-initiated clinical trials have been incorporating new agents into neoadjuvant breast cancer treatment. A/Prof McCarthy has been the Chair of the Systemic Therapy Subcommittee of the ANZ Breast Cancer Trials Group Scientific Advisory Committee (SAC) since 2007 and a member of the SAC since 2004. She has been the Australian Principal Investigator on several international clinical trials. A/Prof McCarthy has been a member of a number of national breast cancer guideline panels and has played a close role with breast cancer consumer advocacy groups.

Associate Professor Nirmala Pathmanathan, BSc (Med), MB, BS, FRCPA, MIACAssociate Professor Nirmala Pathmanathan is an anatomical pathologist with expertise in breast diseases. She is the Director of the Westmead Breast Cancer Institute in Sydney, which is a comprehensive multidisciplinary breast cancer program covering Western Sydney. She is also the Director of the BreastScreen Program for Sydney West and the Designated/Lead Pathologist for this program. She is a Clinical Associate Professor with the University of Sydney and Conjoint Associate Professor with the University of Western Sydney. A/Prof Pathmanathan is currently a specialist breast pathologist at Douglass Hanly Moir Pathology (part time).
A/Professor Pathmanathan is the recipient and chief or principal investigator on a number of grant-funded projects and is a past executive committee member of the Australian Breast Cancer Tumour Bank. She is a Member of NBOCC Sentinel Node Biopsy Subgroup and was involved in the development of recommendations for use of Sentinel Node Biopsy in Breast Cancer. Recently, A/Professor Pathmanathan has been a steering committee member in the development and presentation of breast cancer workshops, aimed at improving the quality of breast cancer pathology and HER2 testing in several countries across the Asia Pacific Region. She sits on the Executive Committee for the Australasian Society for Breast Diseases and is a National Clinical Advisory Board Member for BreastScreen Australia. Her primary research interests are in HER2 testing, prognostic markers in ER positive breast cancer and borderline/atypical lesions of the breast.

Dr Allison Rose MB. BS, M. MED, FRANZCR
Director, Northwestern BreastScreen
Head, The Royal Melbourne & The Women’s Hospital Breast Imaging Service Consultant Radiologist, The Royal Melbourne Hospital Associate, University of Melbourne Radiology Department.Dr Allison Rose worked at the Victorian Pilot Program for the Early Detection of Breast Cancer from 1989 under the auspice of The Royal Melbourne Hospital and became Director in 1999. In 2009 she became Head of Breast Imaging for the combined Royal Melbourne & The Women’s Hospital Breast Service & in this role she has led the team to deliver fully integrated comprehensive breast imaging across diagnostic and screening sites. She was instrumental in establishing Breast MRI & MRI guided biopsy for the service and more recently developed protocols for contrast enhanced digital mammography. Her current interests are focussed on risk based tailored breast screening and appropriate staging of diagnosed breast cancer- BreastStage.

Kerry Shanahan has worked as a Breast Care Clinical Nurse Consultant at the Royal Melbourne Hospital for more than 15 years.
Particular areas of interest are survivorship care in early breast cancer & enhancing care in metastatic breast cancer.
She has a role on a number of committees which are involved in initiating new innovations in breast service provision. Kerry has been a member of the organising committee of previous Breast Care Nurse conferences in Melbourne.

Dr Catherine Shannon is Senior Medical Oncologist at the Mater Cancer Care Centre, Director of Medical Oncology Clinical trials unit, a member of Mater Research’s Clinical Research group and Senior Lecturer at the University of Queensland, Brisbane, Australia. She is the Principal or Co-investigator on a number of Phase I, II and III clinical trials in breast and gynaecological cancer. She is currently on the Executive Committee of the Australian Society of Breast Disease and member of the Breast cancer advisory panel for Cancer Australia.
Dr Shannon has a special interest in the management of breast cancer in young women and pregnant women and has published in this field. Dr Shannon recently started a private practice at the Mater Cancer Care Centre in South Brisbane. Her research publications include the molecular genetics of synchronous gynaecological tumours and neoadjuvant therapies for breast cancer. Dr Shannon acted as Chair at the committee for writing endocrine therapy guidelines for the management of advanced breast cancer.

Lisa is a Breast Care Nurse Coordinator at The Peter Mac Callum Cancer Centre and has over 18 years’ experience working at Peter Mac. She has predominantly worked in the breast cancer area with 10 years’ experience working in Nursing and Supportive Care Research.
Lisa has been a member of the organising committee of the past three Breast Care Nurse Conferences held in Melbourne.

Associate Professor of Surgical Oncology
The University of Sydney, Northern Clinical School
Breast and Surgical Oncology at the Poche Centre
Melanoma Institute Australia
Mater Hospital North Sydney
Royal North Shore Hospital, Northern Sydney Cancer Centre
Immediate Past President, BreastSurgANZ

Dr Lesley Stafford BA(Hons) MA(Psych) MPsych(Clin) PhD is the Head of Clinical Psychology at the Royal Women’s Hospital. Her role at the Women’s has included establishing both a clinical psycho-oncology service and a formal psycho-oncology research program. Dr Stafford initially studied in South Africa before completing further clinical training and a PhD at the University of Melbourne, where she is a Senior Lecturer. Her research interests are in the psychological aspects of cancer, specifically, developing sustainable interventions to optimize the quality of life of those affected by cancer. Her clinical work is predominantly with women with breast cancer and those at high risk of developing cancer.

Associate Professor Nicholas Wilcken MB BS, PhD, FRACP
Nicholas Wilcken is Director of Medical Oncology at the Crown Princess Mary Cancer Centre Westmead, Senior Staff Specialist at Nepean Hospital, and Associate Professor of Medicine, University of Sydney, Australia.
Medical oncology training was at Royal Prince Alfred Hospital, Sydney, followed by a PhD in breast cancer cell cycle control at the Garvan Institute, Sydney.
His clinical interests are in breast cancer and colo-rectal cancer. Research interests include translational oncology, systematic reviews and breast cancer clinical trials.
He is currently the Co-ordinating Editor of the Cochrane Collaboration’s Breast Cancer Group and Chair of the ANZ Breast Cancer Trials Group, Scientific Advisory Committee. He has been an invited expert panel member for the last two St Gallen Early Breast Cancer Consensus Conferences in Switzerland and is a member of the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group, based in Oxford, UK.